Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 5/20 | 0.33 |
| ▸ | LMNA | P02545 | 5/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1037105 | 0.95 | CYP2C9 (0.35) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL1517885 | 0.94 | CYP2C9 (0.34) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL1517882 | 0.94 | CYP2C9 (0.34) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL2916459 | 0.93 | FKBP1A (0.38) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL2922625 | 0.93 | FKBP1A (0.38) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL2916456 | 0.93 | FKBP1A (0.38) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL1036293 | 0.93 | CYP2C9 (0.35) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL1040027 | 0.92 | CYP2C9 (0.34) | CYP2C9POLBRORCLMNASMN1; SMN2 | |
| SCHEMBL1038641 | 0.92 | LMNA (0.33) | CYP2C9POLBLMNASMN1; SMN2PKM | |
| SCHEMBL2922224 | 0.92 | CYP2C9 (0.34) | CYP2C9POLBRORCLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049514-B1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2011-01-26 | — | — | EP | disclosed |
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2049514-A1 | NITRATE ESTERS OF PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008017685-A1 | NITRATE ESTERS OF PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325947-A1 | NITRATE ESTERS OF PIPERIDINES | NOS2, NOS1, NOS3 | CYP2C9 882/4885POLB 1015/4885RORC 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.